Explore by Category
The Positive Effect of Consolidation Therapy in Multiple Myeloma
MYELOMA NEWS - January 18, 2021
It always interesting to talk to fellow multiple myeloma patients and learn about different treatment regimens and experiences they have had compared to ou... Read More
Treating High Risk Multiple Myeloma Patients With or Without Elotuzumab: Is There Benefit for Everyone with Quad Therapies?
MYELOMA NEWS - January 11, 2021
Quad therapies are getting more attention as they may help extend or deepen responses for myeloma patients. Does the strategy work for high-risk patients as wel... Read More
An On/Off Switch for CAR T Therapy in Multiple Myeloma
MYELOMA NEWS - January 07, 2021
CAR T therapy is in development for multiple myeloma, but can come with toxic side effects called cytokine release syndrome, an overactive inflammatory res... Read More
ASH 2020: New Off-the-Shelf CAR T Early Results for Multiple Myeloma
MYELOMA NEWS - January 01, 2021
Early Results with Allo-CAR-T Products Allo-715 and Allo-647 Many interesting presentations were given at the most recent ‘virtual’ multi-day con... Read More
Janssen Starts Rolling Submission of FDA Biologics License Application for cilta-cel Myeloma CAR-T Treatment
MYELOMA NEWS - January 01, 2021
In late December, Janssen announced that it began the rolling submission of its Biologics License Application to the FDA for their CAR T therapy called ciltacab... Read More
ASH 2020: Pathways Targeting Genetics of Myeloma Reconsidered
MYELOMA NEWS - December 30, 2020
Inactivating the genetic mechanisms that cause malignancy by inhibiting gene mutations is an effective treatment for a number of cancers but has ... Read More
Fast Development of COVID Vaccine: Not A Reason for Concern
MYELOMA NEWS - December 24, 2020
Swift development of COVID-19 vaccines has caused some people to question their safety and wonder if corners were cut in its rapid development. Phase I, I... Read More
ASH 2020: Five Myeloma Experts Discuss Treatment Preferences
MYELOMA NEWS - December 22, 2020
“Initial treatment is the best chance for a deep and durable response. It is most important to get a deep response.” Nikhil Munshi, Dana-... Read More
ASH 2020: Is More Better? Triplet vs. Quadruplet Drug Combinations in Newly Diagnosed Myeloma
MYELOMA NEWS - December 22, 2020
The process of making treatment decisions usually involves comparing treatments; their side effects and outcomes to determine what is the best choice for you. T... Read More
ASH 2020: The State of Myeloma Drug Development Remains Strong as CAR T Races On
MYELOMA NEWS - December 18, 2020
While there are 7,000 orphan diseases globally, there are only 500 drugs available to treat all 7,000 diseases. In September of last year I wrote a blog po... Read More
FDA Approves Selinexor for use After First Line Multiple Myeloma Therapy
MYELOMA NEWS - December 18, 2020
The FDA approved today the use of the oral drug XPOVIO® (Selinexor) as a treatment for multiple myeloma patients who have relapsed after their first line of... Read More
ASH 2020: High Risk Smoldering Myeloma-Is It Time To Treat?
MYELOMA NEWS - December 16, 2020
The debate over when and how to treat high risk smoldering multiple myeloma patients (HRSMM) has heated up again at this year's ASH conference. HRSMM is def... Read More
Persistence Brings New Myeloma Therapy to Light
MYELOMA NEWS - December 15, 2020
Researchers have shown in the past that the protein complex NF-κB (nuclear factor kappa light chain enhancer of activated B-cells) controls several d... Read More
